EUCTR2018-004445-17-DK进行中（未招募）1 期
A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study of AP30663 Given Intravenously for Cardioversion in Patients with Atrial Fibrillation
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for study entry, patients must satisfy all of the following criteria:
- •1. Provision of written informed consent.
- •2. Clinical indication for cardioversion of atrial fibrillation.
- •3. Current episode of symptomatic atrial fibrillation lasting between 3 h and 7 days inclusive at randomisation.
- •4. Adequate anticoagulation according to international and/or national guidelines.
- •5. Body weight 50 to 110 kg inclusive (with clothes, without shoes).
- •6. Male patients and postmenopausal women aged 18 to 80 years inclusive.
- •- Male patients who are sexually active must agree to abstain from sexual activity or be willing to use a double-barrier method of birth control (i.e. any double combination of male or female condom with spermicidal gel, diaphragm, sponge or cervical cap with spermicidal gel) if they become sexually active from the time of consent and for 90 days after the infusion day.
- •- Post-menopausal women are defined as being >12 months after last menstrual period.
- •- Women can also be included if permanently sterilised since =6 weeks (i.e. documented hysterectomy, bilateral salpingectomy, bilateral oophorectomy). Breastfeeding women are excluded.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 43
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 65
排除标准
- •1. Significant clinical illness or surgical procedure within 4 weeks preceding the screening visit.
- •2. Present renal dysfunction (estimated glomerular filtration rate [eGFR] <30 mL/min), hepatic dysfunction (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >3 × upper limit of normal), or uncontrolled hyperthyroidism or hypothyroidism.
- •3. History of significant mental, renal or hepatic disorder, chronic obstructive pulmonary disease or other significant disease, as judged by the investigator.
- •4. Any cardioversion attempt of AF or atrial flutter within 1 week preceding randomisation.
- •5. Prior failed attempt (no conversion) of pharmacological or DC cardioversion of previous or current AF episode.
- •6. Failure to find a large antecubital (or equivalent) vein for the infusion.
- •7. Any of the following events, or any other significant cardiovascular event as judged by the investigator, during the last 6 weeks before randomisation: myocardial infarction, unstable angina pectoris or other signs of myocardial ischaemia, stroke or transient ischaemic attack, myocardial revascularisation (percutaneous coronary intervention [PCI], coronary artery bypass graft [CABG]), or other revascularisation procedure.
- •8. Haemodynamically unstable condition as judged by the investigator; systolic blood pressure (BP) <90 mm Hg or >180 mm Hg, or diastolic BP >105 mm Hg at randomisation.
- •9. Blood haemoglobin <100 g/L at screening.
- •10. Congestive heart failure New York Heart Association class III or IV. Left ventricular ejection fraction <40% on echocardiography, or other clinically significant abnormality on the echocardiogram (not older than 6 months) as judged by the investigator.
- •11. Known hypertrophic cardiomyopathy or significant left ventricular hypertrophy (free wall or septal thickness >13 mm).
- •12. Any clinically significant valvular heart disease.
- •13. History or previous signs of sinus nodal disease.
- •14. Pacemaker or implantable cardioverter defibrillator therapy.
- •15. Personal or family history of Torsades de Pointes, any other polymorphic ventricular tachycardia, sustained ventricular tachycardia, long QT syndrome, and/or Brugada syndrome.
- •16. QTc (Fridericia, QTcF) interval >450 ms at randomisation. (When measured during AF, the mean heart rate should be 50 to 100 bpm. The QTcF should be calculated at AF as the mean of at least 5 consecutive RR intervals with consecutive QT intervals).
- •17. QRS duration >120 ms at randomisation.
- •18. Known atrioventricular (AV)-block I (prolonged PQ [PR] interval >220 ms), AV-block II, AV-block III, or complete bundle branch block (BBB).
- •19. Potassium in serum below 3.5 or above 5.3 mmol/L at randomisation. Patients with low potassium levels at screening may be appropriately supplemented with potassium before baseline, according to the local standards. A re-test of the potassium level is required, and the patient can be randomised after the potassium has returned to reference range.
- •20. Anticipated change in dose or initiation of loop diuretic from screening to the end of infusion.
- •21. Use of any antiarrhythmic drug class I and/or III within 7 days or, for amiodarone specifically, 12 weeks before randomisation.
- •22. Use of QT-prolonging drug, and/or drug that inhibits cytochrome P450 (CYP)3A4, as well as St John's Wort within 10 days before randomisation.
- •23. Administration of an investigational drug within the preceding 3 months before randomisation.
- •24. Administration of AP30663 at any time before randomis
研究者
相似试验
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II study to Assess the efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients with Cystic Fibrosis.Estudio fase II de distribución aleatoria, doble ciego, controlado con placebo y de grupos paralelos, para evaluar la eficacia de la administración oral durante 28 días de AZD1236 a pacientes adultos con fibrosis quística - CYBERCystic FibrosisFibrosis quísticaMedDRA version: 9.1Level: LLTClassification code 10011763Term: Cystic fibrosis lungEUCTR2008-004699-34-ESAstraZeneca AB50
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel-group, Multicentre, 24 week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300 mcg/day) in Naturally Menopausal Women with Hypoactive Sexual Desire Disorder Receiving Systemic Transdermal Estrogen, Oral Non-Conjugated Equine Estrogen, or No Estrogen Therapy - ADOREHypoactive sexual desire disorderEUCTR2006-001179-39-DEProcter & Gamble Pharmaceuticals270
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by the Respimat Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD)EUCTR2006-001009-27-HUBoehringer Ingelheim Pharma GesmbH3,000
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily compared with Placebo for 24 Weeks in Adult Subjects with Chronic Obstructive Pulmonary Disease (COPD).EUCTR2010-019695-76-EEGlaxoSmithKline Research & Development675
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 52 Weeks in Adult and Adolescent Subjects with Perennial Allergic RhinitisPerennial allergic rhinitisEUCTR2004-000091-14-LTGlaxoSmithKline736